CT-P47

BIOLOGICAL3 trials

Sponsors

Celltrion

Conditions

Healthy SubjectsRheumatoid Arthritis

Phase 1

A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects

CelltrionHealthy Subjects

Start: 2021-12-22End: 2023-01-31Target: 300Updated: 2022-01-12

Compare the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy Subjects

CelltrionHealthy Subjects

Start: 2022-11-15End: 2023-09-30Target: 268Updated: 2023-03-27

Phase 3

A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis

CompletedNCT05489224

CelltrionRheumatoid Arthritis

Start: 2022-09-14End: 2023-11-23Updated: 2024-10-08

Related Papers

Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis

Clinical Drug Investigation2025-07-121 citations

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study

Expert Opinion on Biological Therapy2024-06-213 citations

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study

Expert Opinion on Investigational Drugs2023-05-0411 citations